APO Research
Talk to an analyst

APO RESEARCH · REPORT

Acinetobacter Infections Treatment

Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or “species” of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or “species” of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.

Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.

Acinetobacter is often resistant to many commonly prescribed antibiotics. Decisions on treatment of infections with Acinetobacter should be made on a case-by-case basis by a healthcare provider. Acinetobacter infection typically occurs in ill patients and can either cause or contribute to death in these patients.

Selected research

Market Outlook & Growth Opportunities

Global Acinetobacter Infections Treatment Market Outlook and Growth Opportunities 2026

2 January 2026196 pages

Choose your research edition.

Industry ResearchAcinetobacter Infections Treatment Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Acinetobacter Infections Treatment Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Acinetobacter Infections Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Acinetobacter Infections Treatment Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Acinetobacter Infections Treatment Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or “species” of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.

Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.

Acinetobacter is often resistant to many commonly prescribed antibiotics. Decisions on treatment of infections with Acinetobacter should be made on a case-by-case basis by a healthcare provider. Acinetobacter infection typically occurs in ill patients and can either cause or contribute to death in these patients.

Read the full market overview

In the American market, Major manufacturers include Entasis Therapeutics, Roche, Adenium Biotech, Vaxdyn, Hsiri Therapeutics, Aridis Pharmaceuticals, and Legochem Biosciences, Atterx Biotherapeutics, Achaogen, Peptilogics, Sealife Pharma, Shionogi, Techulon and Tetraphase Pharmaceuticals, among others. Entasis Therapeutics, Roche and Adenium Biotech are the top 3 players of Acinetobacter Infections Treatment, with about 66% market shares.

This report provides an overview of the global Acinetobacter Infections Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Acinetobacter Infections Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Acinetobacter Infections Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Acinetobacter Infections Treatment market.

Acinetobacter Infections Treatment Segment by Company

Entasis Therapeutics

Roche

Adenium Biotech

Vaxdyn

Hsiri Therapeutics

Aridis Pharmaceuticals

LegoChem Biosciences

Atterx Biotherapeutics

Achaogen

Peptilogics

Sealife PHARMA

Shionogi

Techulon

Tetraphase Pharmaceuticals

Acinetobacter Infections Treatment Segment by Type

Sulbactam

Carbapenems

Aminoglycosides

Polymyxins

Tetracyclines

Others

Acinetobacter Infections Treatment Segment by Pipeline

ETX2514

Nacubactam RG6080

Arenicin

VXD-001

Small Molecule Antibiotic

AR-401 mAB

LCB01-0371 (PO)

GN-4474

Antibacterial Antibody

Others

Acinetobacter Infections Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Acinetobacter Infections Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Acinetobacter Infections Treatment key companies, revenue, market share, and recent developments.

3. To split the Acinetobacter Infections Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Acinetobacter Infections Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Acinetobacter Infections Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Acinetobacter Infections Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acinetobacter Infections Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Acinetobacter Infections Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acinetobacter Infections Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Acinetobacter Infections Treatment industry.

Chapter 3: Detailed analysis of Acinetobacter Infections Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Acinetobacter Infections Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Acinetobacter Infections Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Acinetobacter Infections Treatment Industry Trends Table 2. Acinetobacter Infections Treatment Industry Drivers Table 3. Acinetobacter Infections Treatment Industry Opportunities and Challenges Table 4. Acinetobacter Infections Treatment Industry Restraints Table 5. Global Acinetobacter Infections Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Acinetobacter Infections Treatment Revenue Share by Company (2021-2026) Table 7. Global Acinetobacter Infections Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Acinetobacter Infections Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Acinetobacter Infections Treatment Company, Product Type & Application Table 10. Global Acinetobacter Infections Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Acinetobacter Infections Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Sulbactam Table 15. Significant Companies of Carbapenems Table 16. Significant Companies of Aminoglycosides Table 17. Significant Companies of Polymyxins Table 18. Significant Companies of Tetracyclines Table 19. Significant Companies of Others Table 20. Global Acinetobacter Infections Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global Acinetobacter Infections Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global Acinetobacter Infections Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global Acinetobacter Infections Treatment Sales Value Share by Type (2021-2026) Table 24. Global Acinetobacter Infections Treatment Sales Value Share by Type (2027-2032) Table 25. Significant Companies of ETX2514 Table 26. Significant Companies of Nacubactam RG6080 Table 27. Significant Companies of Arenicin Table 28. Significant Companies of VXD-001 Table 29. Significant Companies of Small Molecule Antibiotic Table 30. Significant Companies of AR-401 mAB Table 31. Significant Companies of LCB01-0371 (PO) Table 32. Significant Companies of GN-4474 Table 33. Significant Companies of Antibacterial Antibody Table 34. Significant Companies of Others Table 35. Global Acinetobacter Infections Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Acinetobacter Infections Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 37. Global Acinetobacter Infections Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 38. Global Acinetobacter Infections Treatment Sales Value Share by Application (2021-2026) Table 39. Global Acinetobacter Infections Treatment Sales Value Share by Application (2027-2032) Table 40. Global Acinetobacter Infections Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Acinetobacter Infections Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 42. Global Acinetobacter Infections Treatment Sales Value Share by Region (2021-2026) Table 43. Global Acinetobacter Infections Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 44. Global Acinetobacter Infections Treatment Sales Value Share by Region (2027-2032) Table 45. Global Acinetobacter Infections Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Acinetobacter Infections Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 47. Global Acinetobacter Infections Treatment Sales Value Market Share by Country (2021-2026) Table 48. Global Acinetobacter Infections Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 49. Global Acinetobacter Infections Treatment Sales Value Market Share by Country (2027-2032) Table 50. Entasis Therapeutics Company Information Table 51. Entasis Therapeutics Business Overview Table 52. Entasis Therapeutics Acinetobacter Infections Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Entasis Therapeutics Acinetobacter Infections Treatment Product Portfolio Table 54. Entasis Therapeutics Recent Development Table 55. Roche Company Information Table 56. Roche Business Overview Table 57. Roche Acinetobacter Infections Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Roche Acinetobacter Infections Treatment Product Portfolio Table 59. Roche Recent Development Table 60. Adenium Biotech Company Information Table 61. Adenium Biotech Business Overview Table 62. Adenium Biotech Acinetobacter Infections Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Adenium Biotech Acinetobacter Infections Treatment Product Portfolio Table 64. Adenium Biotech Recent Development Table 65. Vaxdyn Company Information Table 66. Vaxdyn Business Overview Table 67. Vaxdyn Acinetobacter Infections Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Vaxdyn Acinetobacter Infections Treatment Product Portfolio Table 69. Vaxdyn Recent Development Table 70. Hsiri Therapeutics Company Information Table 71. Hsiri Therapeutics Business Overview Table 72. Hsiri Therapeutics Acinetobacter Infections Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Hsiri Therapeutics Acinetobacter Infections Treatment Product Portfolio Table 74. Hsiri Therapeutics Recent Development Table 75. Aridis Pharmaceuticals Company Information Table 76. Aridis Pharmaceuticals Business Overview Table 77. Aridis Pharmaceuticals Acinetobacter Infections Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Aridis Pharmaceuticals Acinetobacter Infections Treatment Product Portfolio Table 79. Aridis Pharmaceuticals Recent Development Table 80. LegoChem Biosciences Company Information Table 81. LegoChem Biosciences Business Overview Table 82. LegoChem Biosciences Acinetobacter Infections Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. LegoChem Biosciences Acinetobacter Infections Treatment Product Portfolio Table 84. LegoChem Biosciences Recent Development Table 85. Atterx Biotherapeutics Company Information Table 86. Atterx Biotherapeutics Business Overview Table 87. Atterx Biotherapeutics Acinetobacter Infections Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Atterx Biotherapeutics Acinetobacter Infections Treatment Product Portfolio Table 89. Atterx Biotherapeutics Recent Development Table 90. Achaogen Company Information Table 91. Achaogen Business Overview Table 92. Achaogen Acinetobacter Infections Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Achaogen Acinetobacter Infections Treatment Product Portfolio Table 94. Achaogen Recent Development Table 95. Peptilogics Company Information Table 96. Peptilogics Business Overview Table 97. Peptilogics Acinetobacter Infections Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Peptilogics Acinetobacter Infections Treatment Product Portfolio Table 99. Peptilogics Recent Development Table 100. Sealife PHARMA Company Information Table 101. Sealife PHARMA Business Overview Table 102. Sealife PHARMA Acinetobacter Infections Treatment Sales (Cases), Value (US$ Million), Price (USD/Case) and Gross Margin (2021-2026) Table 103. Sealife PHARMA Acinetobacter Infections Treatment Product Portfolio Table 104. Sealife PHARMA Recent Development Table 105. Shionogi Company Information Table 106. Shionogi Business Overview Table 107. Shionogi Acinetobacter Infections Treatment Sales (Cases), Value (US$ Million), Price (USD/Case) and Gross Margin (2021-2026) Table 108. Shionogi Acinetobacter Infections Treatment Product Portfolio Table 109. Shionogi Recent Development Table 110. Techulon Company Information Table 111. Techulon Business Overview Table 112. Techulon Acinetobacter Infections Treatment Sales (Cases), Value (US$ Million), Price (USD/Case) and Gross Margin (2021-2026) Table 113. Techulon Acinetobacter Infections Treatment Product Portfolio Table 114. Techulon Recent Development Table 115. Tetraphase Pharmaceuticals Company Information Table 116. Tetraphase Pharmaceuticals Business Overview Table 117. Tetraphase Pharmaceuticals Acinetobacter Infections Treatment Sales (Cases), Value (US$ Million), Price (USD/Case) and Gross Margin (2021-2026) Table 118. Tetraphase Pharmaceuticals Acinetobacter Infections Treatment Product Portfolio Table 119. Tetraphase Pharmaceuticals Recent Development Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Acinetobacter Infections Treatment Product Image Figure 2. Global Acinetobacter Infections Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Acinetobacter Infections Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Acinetobacter Infections Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Sulbactam Image Figure 8. Carbapenems Image Figure 9. Aminoglycosides Image Figure 10. Polymyxins Image Figure 11. Tetracyclines Image Figure 12. Others Image Figure 13. Global Acinetobacter Infections Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global Acinetobacter Infections Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global Acinetobacter Infections Treatment Sales Value Share by Type (2021-2032) Figure 16. ETX2514 Image Figure 17. Nacubactam RG6080 Image Figure 18. Arenicin Image Figure 19. VXD-001 Image Figure 20. Small Molecule Antibiotic Image Figure 21. AR-401 mAB Image Figure 22. LCB01-0371 (PO) Image Figure 23. GN-4474 Image Figure 24. Antibacterial Antibody Image Figure 25. Others Image Figure 26. Global Acinetobacter Infections Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Acinetobacter Infections Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Acinetobacter Infections Treatment Sales Value Share by Application (2021-2032) Figure 29. Global Acinetobacter Infections Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Acinetobacter Infections Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Acinetobacter Infections Treatment Sales Value (2021-2032) & (US$ Million) Figure 32. North America Acinetobacter Infections Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Acinetobacter Infections Treatment Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Acinetobacter Infections Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Acinetobacter Infections Treatment Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Acinetobacter Infections Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Acinetobacter Infections Treatment Sales Value (2021-2032) & (US$ Million) Figure 38. South America Acinetobacter Infections Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Acinetobacter Infections Treatment Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Acinetobacter Infections Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Years Considered Figure 126. Research Process Figure 127. Key Executives Interviewed

Scope & coverage.

Types
  • Sulbactam
  • Carbapenems
  • Aminoglycosides
  • Polymyxins
  • Tetracyclines
  • Others
Applications
  • ETX2514
  • Nacubactam RG6080
  • Arenicin
  • VXD-001
  • Small Molecule Antibiotic
  • AR-401 mAB
  • LCB01-0371 (PO)
  • GN-4474
  • Antibacterial Antibody
  • Others
Companies covered
  • Entasis Therapeutics
  • Roche
  • Adenium Biotech
  • Vaxdyn
  • Hsiri Therapeutics
  • Aridis Pharmaceuticals
  • LegoChem Biosciences
  • Atterx Biotherapeutics
  • Achaogen
  • Peptilogics
  • Sealife PHARMA
  • Shionogi
  • Techulon
  • Tetraphase Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Acinetobacter Infections Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Acinetobacter Infections Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Acinetobacter Infections Treatment Market Dynamics
  1. 2.1 Acinetobacter Infections Treatment Industry Trends
  2. 2.2 Acinetobacter Infections Treatment Industry Drivers
  3. 2.3 Acinetobacter Infections Treatment Industry Opportunities and Challenges
  4. 2.4 Acinetobacter Infections Treatment Industry Restraints
3 Acinetobacter Infections Treatment Market by Company
  1. 3.1 Global Acinetobacter Infections Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Acinetobacter Infections Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Acinetobacter Infections Treatment Company Ranking (2024-2026)
  4. 3.4 Global Acinetobacter Infections Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Acinetobacter Infections Treatment Company Product Type and Application
  6. 3.6 Global Acinetobacter Infections Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Acinetobacter Infections Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Acinetobacter Infections Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Acinetobacter Infections Treatment Market by Type
  1. 4.1 Acinetobacter Infections Treatment Type Introduction
  2. 4.1.1 Sulbactam
  3. 4.1.2 Carbapenems
  4. 4.1.3 Aminoglycosides
  5. 4.1.4 Polymyxins
  6. 4.1.5 Tetracyclines
  7. 4.1.6 Others
  8. 4.2 Global Acinetobacter Infections Treatment Sales Value by Type
  9. 4.2.1 Global Acinetobacter Infections Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Acinetobacter Infections Treatment Sales Value by Type (2021-2032)
  11. 4.2.3 Global Acinetobacter Infections Treatment Sales Value Share by Type (2021-2032)
5 Acinetobacter Infections Treatment Market by Application
  1. 5.1 Acinetobacter Infections Treatment Application Introduction
  2. 5.1.1 ETX2514
  3. 5.1.2 Nacubactam RG6080
  4. 5.1.3 Arenicin
  5. 5.1.4 VXD-001
  6. 5.1.5 Small Molecule Antibiotic
  7. 5.1.6 AR-401 mAB
  8. 5.1.7 LCB01-0371 (PO)
  9. 5.1.8 GN-4474
  10. 5.1.9 Antibacterial Antibody
  11. 5.1.10 Others
  12. 5.2 Global Acinetobacter Infections Treatment Sales Value by Application
  13. 5.2.1 Global Acinetobacter Infections Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  14. 5.2.2 Global Acinetobacter Infections Treatment Sales Value by Application (2021-2032)
  15. 5.2.3 Global Acinetobacter Infections Treatment Sales Value Share by Application (2021-2032)
6 Acinetobacter Infections Treatment Regional Value Analysis
  1. 6.1 Global Acinetobacter Infections Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Acinetobacter Infections Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Acinetobacter Infections Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Acinetobacter Infections Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Acinetobacter Infections Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Acinetobacter Infections Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Acinetobacter Infections Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Acinetobacter Infections Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Acinetobacter Infections Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Acinetobacter Infections Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Acinetobacter Infections Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Acinetobacter Infections Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Acinetobacter Infections Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Acinetobacter Infections Treatment Sales Value Share by Country, 2025 VS 2032
7 Acinetobacter Infections Treatment Country-level Value Analysis
  1. 7.1 Global Acinetobacter Infections Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Acinetobacter Infections Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Acinetobacter Infections Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Acinetobacter Infections Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Acinetobacter Infections Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Acinetobacter Infections Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Acinetobacter Infections Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Entasis Therapeutics
  2. 8.1.1 Entasis Therapeutics Company Information
  3. 8.1.2 Entasis Therapeutics Business Overview
  4. 8.1.3 Entasis Therapeutics Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Entasis Therapeutics Acinetobacter Infections Treatment Product Portfolio
  6. 8.1.5 Entasis Therapeutics Recent Developments
  7. 8.2 Roche
  8. 8.2.1 Roche Company Information
  9. 8.2.2 Roche Business Overview
  10. 8.2.3 Roche Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Roche Acinetobacter Infections Treatment Product Portfolio
  12. 8.2.5 Roche Recent Developments
  13. 8.3 Adenium Biotech
  14. 8.3.1 Adenium Biotech Company Information
  15. 8.3.2 Adenium Biotech Business Overview
  16. 8.3.3 Adenium Biotech Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Adenium Biotech Acinetobacter Infections Treatment Product Portfolio
  18. 8.3.5 Adenium Biotech Recent Developments
  19. 8.4 Vaxdyn
  20. 8.4.1 Vaxdyn Company Information
  21. 8.4.2 Vaxdyn Business Overview
  22. 8.4.3 Vaxdyn Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Vaxdyn Acinetobacter Infections Treatment Product Portfolio
  24. 8.4.5 Vaxdyn Recent Developments
  25. 8.5 Hsiri Therapeutics
  26. 8.5.1 Hsiri Therapeutics Company Information
  27. 8.5.2 Hsiri Therapeutics Business Overview
  28. 8.5.3 Hsiri Therapeutics Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Hsiri Therapeutics Acinetobacter Infections Treatment Product Portfolio
  30. 8.5.5 Hsiri Therapeutics Recent Developments
  31. 8.6 Aridis Pharmaceuticals
  32. 8.6.1 Aridis Pharmaceuticals Company Information
  33. 8.6.2 Aridis Pharmaceuticals Business Overview
  34. 8.6.3 Aridis Pharmaceuticals Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Aridis Pharmaceuticals Acinetobacter Infections Treatment Product Portfolio
  36. 8.6.5 Aridis Pharmaceuticals Recent Developments
  37. 8.7 LegoChem Biosciences
  38. 8.7.1 LegoChem Biosciences Company Information
  39. 8.7.2 LegoChem Biosciences Business Overview
  40. 8.7.3 LegoChem Biosciences Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 LegoChem Biosciences Acinetobacter Infections Treatment Product Portfolio
  42. 8.7.5 LegoChem Biosciences Recent Developments
  43. 8.8 Atterx Biotherapeutics
  44. 8.8.1 Atterx Biotherapeutics Company Information
  45. 8.8.2 Atterx Biotherapeutics Business Overview
  46. 8.8.3 Atterx Biotherapeutics Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Atterx Biotherapeutics Acinetobacter Infections Treatment Product Portfolio
  48. 8.8.5 Atterx Biotherapeutics Recent Developments
  49. 8.9 Achaogen
  50. 8.9.1 Achaogen Company Information
  51. 8.9.2 Achaogen Business Overview
  52. 8.9.3 Achaogen Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Achaogen Acinetobacter Infections Treatment Product Portfolio
  54. 8.9.5 Achaogen Recent Developments
  55. 8.10 Peptilogics
  56. 8.10.1 Peptilogics Company Information
  57. 8.10.2 Peptilogics Business Overview
  58. 8.10.3 Peptilogics Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Peptilogics Acinetobacter Infections Treatment Product Portfolio
  60. 8.10.5 Peptilogics Recent Developments
  61. 8.11 Sealife PHARMA
  62. 8.11.1 Sealife PHARMA Company Information
  63. 8.11.2 Sealife PHARMA Business Overview
  64. 8.11.3 Sealife PHARMA Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sealife PHARMA Acinetobacter Infections Treatment Product Portfolio
  66. 8.11.5 Sealife PHARMA Recent Developments
  67. 8.12 Shionogi
  68. 8.12.1 Shionogi Company Information
  69. 8.12.2 Shionogi Business Overview
  70. 8.12.3 Shionogi Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Shionogi Acinetobacter Infections Treatment Product Portfolio
  72. 8.12.5 Shionogi Recent Developments
  73. 8.13 Techulon
  74. 8.13.1 Techulon Company Information
  75. 8.13.2 Techulon Business Overview
  76. 8.13.3 Techulon Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Techulon Acinetobacter Infections Treatment Product Portfolio
  78. 8.13.5 Techulon Recent Developments
  79. 8.14 Tetraphase Pharmaceuticals
  80. 8.14.1 Tetraphase Pharmaceuticals Company Information
  81. 8.14.2 Tetraphase Pharmaceuticals Business Overview
  82. 8.14.3 Tetraphase Pharmaceuticals Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Tetraphase Pharmaceuticals Acinetobacter Infections Treatment Product Portfolio
  84. 8.14.5 Tetraphase Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst